Supercharged immune cells take on HPV cancers

NCT ID NCT05686226

First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This study tests a new immunotherapy for people with advanced HPV-related cancers (cervical, throat, anal, and others). Participants receive specially engineered immune cells designed to attack HPV-infected tumor cells, along with chemotherapy and a drug to boost cell activity. The goal is to see if this treatment can shrink tumors in 20 adults whose cancer has spread or returned.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • RWJBarnabas Health - Robert Wood Johnson University Hospital

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rutgers Cancer Institute

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.